Correction to: LncRNA MYLK-AS1 facilitates tumor progression and angiogenesis by targeting miR-424-5p/E2F7 axis and activating VEGFR-2 signaling pathway in hepatocellular carcinoma
An amendment to this paper has been published and can be accessed via the original article.
Main Authors: | Fei Teng, Ju-Xiang Zhang, Qi-Meng Chang, Xu-Bo Wu, Wei-Guo Tang, Jian-Fa Wang, Jin-Feng Feng, Zi-Ping Zhang, Zhi-Qiu Hu |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-12-01
|
Series: | Journal of Experimental & Clinical Cancer Research |
Online Access: | https://doi.org/10.1186/s13046-020-01780-y |
Similar Items
-
LncRNA MYLK-AS1 facilitates tumor progression and angiogenesis by targeting miR-424-5p/E2F7 axis and activating VEGFR-2 signaling pathway in hepatocellular carcinoma
by: Fei Teng, et al.
Published: (2020-11-01) -
lncRNA LOC100132354 promotes angiogenesis through VEGFA/VEGFR2 signaling pathway in lung adenocarcinoma
by: Wang Y, et al.
Published: (2018-10-01) -
Exosomal lncRNA RAMP2-AS1 Derived from Chondrosarcoma Cells Promotes Angiogenesis Through miR-2355-5p/VEGFR2 Axis
by: Cheng C, et al.
Published: (2020-04-01) -
LncRNA MYLK-AS1 acts as an oncogene by epigenetically silencing large tumor suppressor 2 (LATS2) in gastric cancer
by: Juan Luo, et al.
Published: (2021-01-01) -
LncRNA NKX2‐1‐AS1 promotes tumor progression and angiogenesis via upregulation of SERPINE1 expression and activation of the VEGFR‐2 signaling pathway in gastric cancer
by: Fei Teng, et al.
Published: (2021-04-01)